The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
Open accessAbstract
We evaluated neoadjuvant ipilimumab in patients with surgically operable regionally advanced melanoma in order to define markers of activity in the blood and tumor as assessed at baseline (before ipilimumab) and early on-treatment. Patients were treated with ipilimumab (10 mg/kg intravenously every 3 weeks ×2 doses) bracketing surgery. Tumor and blood biospecimens were obtained at baseline and at surgery. Flow cytometry and immunohistochemistry for select biomarkers were performed. Thirty five patients were enrolled; IIIB (3; N2b), IIIC (32; N2c, N3), IV (2). Worst toxicities included Grade 3 diarrhea/colitis (5; 14%), hepatitis (2; 6%), rash (1; 3%), elevated lipase (3; 9%). Median follow up was 18 months: among 33 evaluable patients, median progression free survival (PFS) was 11 months, 95% CI (6.2-19.2). There was a significant decrease in circulating myeloid derived suppressor cells (MDSC). Greater decrease in circulating monocyte gate MDSC Lin1-/HLA-DR-/CD33⁺/CD11b⁺ was associated with improved PFS (p = 0.03). There was a significant increase in circulating regulatory T cells (Treg; CD4⁺CD25hi⁺Foxp3⁺) that, unexpectedly, was associated with improved PFS (HR = 0.57; p = 0.034). Baseline evidence of fully activated type I CD4⁺ and CD8⁺ antigen-specific T cell immunity against cancer-testis (NY-ESO-1) and melanocytic lineage (MART-1, gp100) antigens was detected and was significantly potentiated after ipilimumab. In tumor, there was a significant increase in CD8⁺ T cells after ipilimumab (p = 0.02). Ipilimumab induced increased tumor infiltration by fully activated (CD69⁺) CD3⁺/CD4⁺ and CD3⁺/CD8⁺ T cells with evidence of induction/potentiation of memory T cells (CD45RO⁺). The change in Treg observed within the tumor showed an inverse relationship with clinical benefit and greater decrease in tumor MDSC subset Lin1-/HLA-DR-/CD33⁺/CD11b⁺ was associated with improved PFS at one year. Neoadjuvant evaluation revealed a significant immunomodulating role for ipilimumab on Treg, MDSC and effector T cells in the circulation and tumor microenvironment that warrants further pursuit in the quest for optimizing melanoma immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., White, R. W. D., Sarosdy, M. F., Wood, D. P., Raghavan, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022148 · Cited by 2,668
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
(2002) · The Lancet · doi:10.1016/s0140-6736(02)08651-8 · Cited by 1,459
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Cited by
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Condamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
T cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 604
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
“Two recent clinical studies have identified a reduction in tumor-infiltrating Treg cells after ipilimumab therapy (Romano et al., 2015; Tarhini et al., 2014).”
BackgroundHuang, A. C., & Zappasodi, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01141-1 · Cited by 571
Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 562
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
“However, conflicting results have also been reported (42).”
Reck, M., Luft, A., Szczesna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L., Zielinski, C., Thomas, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6601 · Cited by 538
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Fields, R. C., Fleming, M. D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0018 · Cited by 436
Bishop, J. L., Thaper, D., Vahid, S., Davies, A., Ketola, K., Kuruma, H., Jama, R., Nip, K. M., Angeles, A., Johnson, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1263 · Cited by 418
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0081-1 · Cited by 394
Self-citationNY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Thomas, R., Al-Khadairi, G., Roelands, J., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 393
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386
Weber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Slingluff, C. L., Lawrence, D. P., Logan, T. F., Schuchter, L. M., Nair, S., Fecher, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30126-7 · Cited by 334
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Fischer, G. M., Jalali, A., Kircher, D. A., Lee, W.-C., McQuade, J. L., Haydu, L. E., Joon, A. Y., Reuben, A., de Macedo, M. P., Carapeto, F. C. L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1489 · Cited by 329
Self-citationMechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., & Tartour, E. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 324
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Bishop, J. L., Sio, A., Angeles, A., Roberts, M. E., Azad, A. A., Chi, K. N., & Zoubeidi, A. (2015) · Oncotarget · doi:10.18632/oncotarget.2703 · Cited by 279
Butterfield, L. H. (2015) · BMJ · doi:10.1136/bmj.h988 · Cited by 272
Self-citationTumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
Systemic Therapy for Melanoma: ASCO Guideline
Seth, R., Messersmith, H., Kaur, V., Kirkwood, J. M., Kudchadkar, R., McQuade, J. L., Provenzano, A., Swami, U., Weber, J., Alluri, K. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00198 · Cited by 265
Self-citationGibney, G. T., Kudchadkar, R. R., DeConti, R. C., Thebeau, M. S., Czupryn, M. P., Tetteh, L., Eysmans, C., Richards, A., Schell, M. J., Fisher, K. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2468 · Cited by 258
Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248
Bakos, O., Lawson, C., Rouleau, S., & Tai, L.-H. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0398-7 · Cited by 192
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0249 · Cited by 180
Plitas, G., & Rudensky, A. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033428 · Cited by 148
Regulatory T‐cell heterogeneity and the cancer immune response
Ward‐Hartstonge, K. A., & Kemp, R. A. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.43 · Cited by 122
Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.011 · Cited by 108
Retseck, J., Nasr, A., Lin, Y., Lin, H., Mendiratta, P., Butterfield, L. H., & Tarhini, A. A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1563-y · Cited by 51
Self-citationPersonalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies
Weide, B., Di Giacomo, A. M., Fonsatti, E., & Zitvogel, L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.016 · Cited by 21
Metadata
- Authors
- Tarhini, A. A., Edington, H., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., Rao, U. N. M., & Kirkwood, J. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-03
- Volume
- 9
- Issue
- 2
- Pages
- e87705
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2055901890
- Cited by
- 310
- References
- 37
- FWCI
- 16.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.